CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc.
(Research Triangle Park, NC) have agreed to merge their two companies.
The resulting company's product portfolio will serve three primary
markets: cardiovascular disease, oncology, and immunology.
Medco's products include ATP, an adenosine product under investigation
as an antitumor agent and to prevent the weight loss and wasting
associated with chemotherapy and radiation. Among Repligen's cancer
drugs under development is recombinant platelet factor 4 (rPF4),
which has shown potential as an antiangiogenesis agent.